221 related articles for article (PubMed ID: 8795617)
61. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
62. Heterogeneity of [3H]neurotensin bindings: studies with dynorphin, L-156,903 and levocabastine.
Pettibone DJ; Totaro JA; Harris E; Robinson FM
Brain Res; 1988 Aug; 457(2):212-8. PubMed ID: 2905916
[TBL] [Abstract][Full Text] [Related]
63. Identification of the receptor subtype involved in the analgesic effect of neurotensin.
Dubuc I; Sarret P; Labbé-Jullié C; Botto JM; Honoré E; Bourdel E; Martinez J; Costentin J; Vincent JP; Kitabgi P; Mazella J
J Neurosci; 1999 Jan; 19(1):503-10. PubMed ID: 9870978
[TBL] [Abstract][Full Text] [Related]
64. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
65. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
66. Neurotensin and neuromedin N brain levels after fornix transection: evidence for an efficient neurotensin precursor processing in subicular neurons.
Nicot A; Bidard JN; Kitabgi P; Lhiaubet AM; Masuo Y; Palkovits M; Rostène W; Bérod A
Brain Res; 1995 Dec; 702(1-2):279-83. PubMed ID: 8846090
[TBL] [Abstract][Full Text] [Related]
67. Analysis of binding sites and efficacy of a species-specific peptide at rat and human neurotensin receptors.
Cusack B; Chou T; Jansen K; McCormick DJ; Richelson E
J Pept Res; 2000 Jan; 55(1):72-80. PubMed ID: 10667863
[TBL] [Abstract][Full Text] [Related]
68. Changes in synaptic proteins of the complex PSD-95/NMDA receptor/nNOS and mitochondrial dysfunction after levocabastine treatment.
Lores-Arnaiz S; Karadayian AG; Gutnisky A; Miranda J; Rodríguez de Lores Arnaiz G
Neurochem Int; 2021 Sep; 148():105100. PubMed ID: 34139299
[TBL] [Abstract][Full Text] [Related]
69. Synthesis of a biologically active fluorescent probe for labeling neurotensin receptors.
Faure MP; Gaudreau P; Shaw I; Cashman NR; Beaudet A
J Histochem Cytochem; 1994 Jun; 42(6):755-63. PubMed ID: 8189037
[TBL] [Abstract][Full Text] [Related]
70. Chimeric rat/human neurotensin receptors localize a region of the receptor sensitive to binding of a novel, species-specific, picomolar affinity peptide.
Cusack B; Groshan K; McCormick DJ; Pang YP; Perry R; Phung CT; Souder T; Richelson E
J Biol Chem; 1996 Jun; 271(25):15054-9. PubMed ID: 8662846
[TBL] [Abstract][Full Text] [Related]
71. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.
Gully D; Canton M; Boigegrain R; Jeanjean F; Molimard JC; Poncelet M; Gueudet C; Heaulme M; Leyris R; Brouard A
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):65-9. PubMed ID: 8380498
[TBL] [Abstract][Full Text] [Related]
72. Pharmacological and molecular characterization of the neurotensin receptor expressed in Sf9 cells.
Boudin H; Labrecque J; Lhiaubet AM; Dennis M; Rostène W; Pélaprat D
Biochem Pharmacol; 1996 May; 51(9):1243-6. PubMed ID: 8645349
[TBL] [Abstract][Full Text] [Related]
73. Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation--a review.
Kleczkowska P; Lipkowski AW
Eur J Pharmacol; 2013 Sep; 716(1-3):54-60. PubMed ID: 23500196
[TBL] [Abstract][Full Text] [Related]
74. Neurotensin modulates central muscarinic receptors, an effect which does not involve the high-affinity neurotensin receptor (NTS1).
Schneider PG; López Ordieres MG; Rodríguez de Lores Arnaiz G
Regul Pept; 2010 Aug; 163(1-3):37-42. PubMed ID: 20403392
[TBL] [Abstract][Full Text] [Related]
75. Human umbilical vein endothelial cells express high affinity neurotensin receptors coupled to intracellular calcium release.
Schaeffer P; Laplace MC; Savi P; Pflieger AM; Gully D; Herbert JM
J Biol Chem; 1995 Feb; 270(7):3409-13. PubMed ID: 7852427
[TBL] [Abstract][Full Text] [Related]
76. Anatomical substrate for neurotensin-acetylcholine interactions in the rat basal forebrain.
Szigethy E; Wenk GL; Beaudet A
Peptides; 1988; 9(6):1227-34. PubMed ID: 2854624
[TBL] [Abstract][Full Text] [Related]
77. Endogenous CNS expression of neurotensin and neurotensin receptors is altered during the postpartum period in outbred mice.
Driessen TM; Zhao C; Whittlinger A; Williams H; Gammie SC
PLoS One; 2014; 9(1):e83098. PubMed ID: 24416154
[TBL] [Abstract][Full Text] [Related]
78. Distinct regions of C-terminus of the high affinity neurotensin receptor mediate the functional coupling with pertussis toxin sensitive and insensitive G-proteins.
Najimi M; Gailly P; Maloteaux JM; Hermans E
FEBS Lett; 2002 Feb; 512(1-3):329-33. PubMed ID: 11852105
[TBL] [Abstract][Full Text] [Related]
79. Imaging Neurotensin Receptor in Prostate Cancer With
Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z
Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698
[TBL] [Abstract][Full Text] [Related]
80. Neurotensin expression and release in human colon cancers.
Evers BM; Ishizuka J; Chung DH; Townsend CM; Thompson JC
Ann Surg; 1992 Oct; 216(4):423-30; discussion 430-1. PubMed ID: 1329682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
